|Articles|June 9, 2022

A New Era in Viral & Non-Viral Drug Product Manufacturing

With the manufacturing, packaging and quality control capabilities that you need available at scale, Emergent CDMO’s in-house drug product support services for clinical and commercial manufacturing help pave the way for your biotherapeutic or vaccine success. Flexible fill lines, single-use technologies, a large (and growing) production footprint, viral and non-viral platforms — an entire suite of capabilities from Emergent are ready to support your drug product manufacturing initiative. Plus, our size, adaptability, and expertise ideally position us to meet your needs as they evolve.

Our viral drug product manufacturing facility in Rockville, MD is home to the groninger® INTEGRA, a state-of-the-art high-speed fill/finish line. The INTEGRA offers integrated isolator technology and Biosafety Level 2 (BSL2) capabilities, in conjunction with an automated inspection, labeling, and packaging line, ideal for large scale fill/finish manufacturing of viral biotherapeutics and vaccines. The INTEGRA is an integral part of our strategic investment plan to support biopharma innovators in the fight against life-threatening viral diseases. Learn More

Vanrx Overview

The Vanrx SA25 Aseptic Filling Workcell is a state-of-the-art isolator fill line, providing our clients with a high level of sterility assurance and flexibility through an automated handling, filling, and closing process, designed to minimize line losses. If you have a high-value product and require a small-to-moderate batch size, the Vanrx may be the right fit for your program.
Learn more

groninger® FlexPro 50

The groninger® FlexPro 50, located at our Camden site in Baltimore, MD is a state-of-the-art filling suite, utilizing isolator-based technology for the aseptic processing of drug products in pre-sterilized ready-to-use (RTU) syringes, vials, and cartridges. An inline lyophilizer minimizes user intervention through an automated lyophilization loading system. The FlexPro 50 enhances Emergent CDMO's commitment to providing excellence in aseptic fill/finish to meet biopharmas’ diverse needs. Learn more

Development Services Center Overview

Our Development Services Center for Excellence in Gaithersburg, MD offers drug substance and drug product process development, analytical development, lab-scale manufacturing, and early-phase GMP release and stability testing. To learn more about Emergent CDMO's development services, take a 3D Virtual Tour of our Gaithersburg facility.

Related to this article

Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation. | Image Credit: ©HockleyMedia24/peopleimages.com -stock.adobe.com
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Complying with International Pharmacopoeias
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.